Galecto (GLTO) said Monday that following a strategic review it has decided to focus on cancer and liver disease.
The company said it will leverage its clinical asset GB1211, which has shown positive results in clinical studies on non-small cell lung cancer and decompensated cirrhosis. Galecto said it has strengthened its pipeline by acquiring the global rights to BRM-1420, a treatment developed by Bridge Medicines, a company co-founded by Takeda (TAK).
To acquire the global rights to BRM-1420, Galecto said it issued 62,594 shares to Bridge, representing 4.99% of its outstanding shares. It also issued 160.562 shares of Series A preferred stock, convertible into 160,562 common shares, or about 12.8% of its common stock, pending stockholder approval.
Galecto shares fell nearly 26% in recent trading activity.
Price: 8.60, Change: -3.05, Percent Change: -26.18
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.